2025
Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC).
Tang C, Poduval D, Lee S, Panian J, Pandya C, Saidian A, McKay R, Braun D. Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16507.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaICI responseLoss of heterozygosityPrimary RCC tumorsPrimary tumorHLA evolutionary divergenceGene set enrichment analysisPost-treatment samplesRCC tumorsTumors resistant to immune checkpoint inhibitorsResistance to immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsResponse to ICI therapyAdvanced renal cell carcinomaImmune responseClear cell renal cell carcinomaSignatures of immune responsesCaris Life SciencesCell renal cell carcinomaPre-treatment tumorsSingle-sample gene set enrichment analysisDriver gene mutationsFisher's exact testA comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC).
Saad E, El Ahmar N, Simsek B, Jegede O, Matar S, Mohanna R, Yekeduz E, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Van Allen E, Choueiri T, Atkins M, Signoretti S, Braun D. A comprehensive evaluation of gene expression-based signatures for detecting tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2025, 43: 591-591. DOI: 10.1200/jco.2025.43.5_suppl.591.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMature tertiary lymphoid structuresTertiary lymphoid structuresTLS signatureArea under the receiver operating characteristicSignature scoreGene set variation analysisExpression-based signaturesCD8 densityStaining of tumor sectionsTertiary lymphoid structure densityResponse to immunotherapyTreatment naive patientsGene signature scoresGene expression-based signaturesRenal cell carcinomaSpearman correlationGene expression signaturesReceiver operating characteristicPrimary tumorAlternative diagnostic toolCell carcinomaTumor sectionsLymphoid structuresLymphoid aggregatesSacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics
Adin M, Woolf G, Hegde R, Elsamadicy A, Mendel E, Zucconi W, Pucar D, Aygün N. Sacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics. Skeletal Radiology 2025, 1-26. PMID: 39821683, DOI: 10.1007/s00256-024-04862-6.Peer-Reviewed Original ResearchPrimary tumorTumor mimicsImaging findingsAssessment of response to treatmentGerm cell tumorsEvaluation of systemic diseasesResponse to treatmentInsufficiency fracturesSacral massSecondary tumorsCell tumorsPretreatment evaluationDiagnostic challengeLymphoproliferative diseaseClinical detailsMalignant tumorsPrimary modalitySystemic diseaseEwing sarcomaTumorNotochordal remnantsDevelopmental entityEpidemiological factorsDiagnosisMetastasis
2024
Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis
Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B, Guarracino A, Rippon B, Beltran-Visiedo M, Soler-Agesta R, Pannellini T, Fucikova J, Demaria S, Zhou X, Elemento O, Formenti S, Galluzzi L. Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis. Journal Of The National Cancer Institute 2024, djae329. PMID: 39661487, DOI: 10.1093/jnci/djae329.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRadiation therapyFocal RTOverall survivalMammary carcinogenesisPD-1Impact of radiotherapy doseMouse modelPD-1 blockerRT plus immunotherapyPrimary tumor growthPrimary disease controlIncrease local controlCheckpoint inhibitorsRadiotherapy doseHypofractionated RTOS benefitTumor burdenPrimary tumorBreast cancerTumor growthNeoplastic lesionsLocal controlICI sensitivityEffective immunityGold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors
Jiang Y, Cao H, Deng H, Guan L, Langthasa J, Colburg D, Melemenidis S, Cotton R, Aleman J, Wang X, Graves E, Kalbasi A, Pu K, Rao J, Le Q. Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors. Nature Biotechnology 2024, 1-14. PMID: 39448881, DOI: 10.1038/s41587-024-02448-0.Peer-Reviewed Original ResearchStereotactic ablative radiotherapyAnti-tumor immune responseSmall interfering RNAAblative radiotherapyMetastatic tumorsEffect of stereotactic ablative radiotherapyModel of head and neck cancerHead and neck cancerImmunosuppressive cell populationsPD-1 inhibitorsSmall interfering RNA complexesPD-1Primary tumorImmunotherapeutic effectsNeck cancerGranzyme BGal-1Mouse modelPassive deliveryTumorReduced toxicityCell populationsRadiotherapyRadiosensitivityRenal filtration thresholdUtility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.Peer-Reviewed Original ResearchOvarian carcinomaNext generation sequencingPrimary uterine tumorsDiagnostically challenging casesOvarian tumorsPrimary tumorUterine tumorsEndometrial malignancyMetastatic tumorsAdjuvant treatmentClonal relationshipTargeted therapyUtilization of next generation sequencingTumor clonalityGeneration sequencingProtein expression profilesTumorChallenging casesImprove outcomesCarcinomaGold standardGenetic landscapeMalignancyClonalityExpression profilesMetrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522
Corredor G, Harris J, Koyuncu C, Pathak T, Pandav K, Toro P, Yang K, Faraji F, Castro P, Sandulache V, Koyfman S, Nguyen F, Garden A, Caudell J, Jones C, Rosenthal D, Le Q, Lewis J, Madabhushi A. Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and 0522. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s130. DOI: 10.1016/j.ijrobp.2024.07.236.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesDisease-free survivalOverall survivalHazard ratioHPV+ OPSCCPoor survivalRisk of disease-free survivalOropharyngeal squamous cell carcinoma patientsDisease-free survival modelsSquamous cell carcinoma patientsTreated with standard therapyRisk of overall survivalAssociated with overall survivalHigh-risk ptsRisk scoreCell carcinoma patientsRisk of poor survivalSubsets of patientsCox regression modelsLow-risk counterpartsHPV-positivePrimary tumorCarcinoma patientsStandard therapyInstitutional cohortA Comparison of Machine Learning Models to Predict Lymph Node Metastasis with Primary Tumor Transcriptome in Non-Small Cell Lung Cancer
Lee V, Park H, Aneja S, Patel A. A Comparison of Machine Learning Models to Predict Lymph Node Metastasis with Primary Tumor Transcriptome in Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e638. DOI: 10.1016/j.ijrobp.2024.07.1402.Peer-Reviewed Original ResearchNon-small cell lung cancerLymph nodal metastasisCell lung cancerMedian AUCNodal metastasisPrimary tumorEndobronchial ultrasoundNon-small cell lung cancer stagingLung cancerDiagnostic uncertaintyPrediction of nodal metastasisPET-avid lesionsTreatment strategy formulationPrimary lung adenocarcinomaEBUS-guided biopsiesLymph node metastasisPrimary tumor tissuesReceiver operating characteristic curveTumor transcriptomic dataPET-CTNode metastasisNeedle aspirationCT scanNon-smallClinical decision-makingAnalysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
Pereslete A, Hughes M, Martin A, Files J, Nguyen K, Buckley L, Patel A, Moore A, Winer E, Dillon D, Li T, Tolaney S, Lin N, Sammons S. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro-Oncology 2024, 27: 184-194. PMID: 39211994, PMCID: PMC11726339, DOI: 10.1093/neuonc/noae163.Peer-Reviewed Original ResearchHER2-low expressionHER2-lowMetastatic breast cancerHER2-positiveHER2 expressionHER2-0Primary tumorBrain metastasesEstrogen receptorBreast cancerHER2-positive primary tumorsASCO-CAP guidelinesNCI-designated centersMultivariate survival analysisCox proportional hazards modelsAntibody-drug conjugatesProportional hazards modelActive antibody-drug conjugateASCO-CAPHER2 gainHER2 statusInferior survivalOverall survivalIntracranial activityRetrospective analysisSpatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases
Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay S, Hagihara T, Tan A, Teo M, Tan Q, Ng G, Tan J, Ng M, Gwee Y, Walsh R, Law J, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh B, Hong J, Tay R, Teo C, Dings M, Bijlsma M, Lum J, Mathur S, Pietrantonio F, Blum S, van Laarhoven H, Klempner S, Yong W, So J, Chen Q, Tan P, Sundar R. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology 2024, 167: 1384-1398.e4. PMID: 39147169, DOI: 10.1053/j.gastro.2024.08.007.Peer-Reviewed Original ResearchPeritoneal metastasisTumor microenvironmentPrimary tumorTranscoelomic metastasisGastric cancerExpression of therapeutic targetsAssociated with poor prognosisGastric cancer peritoneal metastasisAssociated with increased riskHumanized mouse modelTherapeutic targetComprehensive multi-omics analysisTumor microenvironment signaturesTumor microenvironment alterationsDigital spatial profilingInvestigate molecular alterationsWhole-exome sequencingMatched normal tissuesStromal infiltrationComprehensive molecular characterizationLiver metastasesImmune compositionFGFR2b expressionImprove patient outcomesPredictive markerThyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
García-Goñi M, Vázquez Gutiérrez B, Sanmamed M, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, Chumbiauca E, Martín-Calvo N, Galofré J. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. Endocrine Related Cancer 2024, 31 PMID: 39013402, DOI: 10.1530/erc-24-0064.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune-related adverse eventsRisk of progressionOverall survivalPrimary tumorThyroid dysfunctionPatients treated with immune checkpoint inhibitorsCancer patients treated with immune checkpoint inhibitorsAssociated with higher ORRImmune checkpoint inhibitor regimenTreated with atezolizumabLonger overall survivalCox proportional hazards modelsResponse to treatmentProbability of recurrenceMultivariable-adjusted regressionRisk of mortalityProportional hazards modelIndependent of ageCheckpoint inhibitorsRECIST v1.1Higher ORRCombination therapyUrothelial cancerClinical presentationCurrent management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN GuidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiationApplying genomic analysis to refine unclassified renal cell carcinoma.
Yekeduz E, Braun D, El Hajj Chehade R, Eid M, Labaki C, Machaalani M, Nassar A, Nawfal R, Saad E, Saliby R, Semaan K, Sun M, Hirsch M, Ürün Y, El Zarif T, CHOUEIRI T. Applying genomic analysis to refine unclassified renal cell carcinoma. Journal Of Clinical Oncology 2024, 42: 4551-4551. DOI: 10.1200/jco.2024.42.16_suppl.4551.Peer-Reviewed Original ResearchRenal cell carcinomaClear cell RCCRenal cell carcinoma subtypesAmerican Association for Cancer ResearchPapillary RCCGenomic alterationsOverall survivalCell carcinomaGenomic profilingPapillary renal cell carcinomaSubtype of renal cell carcinomaChromophobe renal cell carcinomaProportion of female patientsClear cell renal cell carcinomaMedian overall survivalCell renal cell carcinomaCo-mutated genesCompare categorical variablesBenjamini-Hochberg correctionOncogenic signaling pathwaysMetastatic sitesFrequent subtype of renal cell carcinomaPrimary tumorChi-square testNF2 alterationsAbstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Tarantino P, Hughes M, Kusmick R, Alder L, Pereslete A, Noteware L, Moore H, Van Swearingen A, Li T, Gupta H, Smith K, Morganti S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li Y, Cherniack A, Prat A, Chan N, Rimm D, Curigliano G, Sammons S, Anders C, Lin N, Tolaney S. Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE). Cancer Research 2024, 84: ps08-09-ps08-09. DOI: 10.1158/1538-7445.sabcs23-ps08-09.Peer-Reviewed Original ResearchMetastatic breast cancerHER2+ diseaseHER2-lowHER2-low diseaseT-DXdActivity of trastuzumabHER2 statusHER2+Overall survivalHER2-0Breast cancerMetastatic diagnosisPrimary tumorFollow-upHormone receptor (HR)-positive tumorsHistory of brain metastasesHER2-low expressionHER2-low statusHER2-negative casesHER2-negative tumorsMedian follow-upArchival tumor samplesDana-Farber Cancer InstituteInterstitial lung diseaseImpact outcomesImmune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, Myers J, Frederick M. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncology 2024, 153: 106729. PMID: 38663156, DOI: 10.1016/j.oraloncology.2024.106729.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaAssociated with clinical outcomesExtranodal extensionLymph node metastasisImmune infiltrationImmune infiltration statusOverall survivalPrimary tumorNode metastasisOral cancerInfiltration statusClinical outcomes of OSCC patientsExtension of lymph node metastasesAssociated with clinical outcomes of patientsAssociated with OS rateLocally advanced oral cancerClinical outcomes of patientsOutcome of OSCC patientsAssociated with poor overall survivalImmune infiltration of tumorsLow immune infiltrationNode negative tumorsAdvanced oral cancerHuman papillomavirus-negativeInfiltration of tumorsAbstract 1497: Humanized mouse model unveils niche conditioning in gastric cancer peritoneal metastasis
Zhao J, Chia D, Her Z, Ma H, Ong X, Tay S, So J, Chen Q, Tan P, Sundar R. Abstract 1497: Humanized mouse model unveils niche conditioning in gastric cancer peritoneal metastasis. Cancer Research 2024, 84: 1497-1497. DOI: 10.1158/1538-7445.am2024-1497.Peer-Reviewed Original ResearchHumanized mouse modelPeritoneal metastasisGastric cancer peritoneal metastasisPrimary tumorAdjacent peritoneumMouse modelTranscoelomic metastasisHost immune systemEpithelial mesenchymal transitionOrthotopic modelAmerican Association for Cancer Research annual meetingsGastric cancerNovel humanized mouse modelNSG modelImmune systemExpression of M2 macrophagesFunctional human cellsPeritoneal disseminationT-regsOrthotopic inoculationDendritic cellsNOD-SCIDImmune infiltrationPeritoneal samplesNormal peritoneumImpact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers
Haider S, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann B, Judson B, Prasad M, Burtness B, Aboian M, Canis M, Reichel C, Baumeister P, Payabvash S. Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers. Journal Of Nuclear Medicine 2024, 65: jnumed.123.266637. PMID: 38514087, PMCID: PMC11927063, DOI: 10.2967/jnumed.123.266637.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaHuman papillomavirusRadiomic featuresIntraclass correlation coefficientCell carcinomaLentiform nucleusHuman papillomavirus statusReceiver-operating-characteristic analysisReceiver-operating-characteristic curvePET radiomic featuresUnivariate logistic regressionF-FDGPrimary tumorTraining cohortValidation cohortRadiomic biomarkersUnivariate analysisInterindividual comparabilityPredictive valueDegree of reproducibilityMedian areaRadiomic markersLogistic regressionAUCSWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]
Kim H, Tangen C, Vaishampayan U, Tripathi A, Patel S, Shuch B, Barata P, Tan A, Esfeller L, Lara P, Sanchez A, Lerner S, Thompson I. SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars And Original Investigations 2024, 42: s4. DOI: 10.1016/j.urolonc.2024.01.044.Peer-Reviewed Original ResearchCytoreductive nephrectomyPrimary tumorImmune checkpointsSystemic therapySurvival outcomesTrials of immune checkpoint inhibitorsHigher neoantigen loadPROBE study designImmune checkpoint inhibitorsSynchronous primary tumorsAdvanced renal cancerWeeks of therapyOverall survival outcomesShorter survival outcomeStandard of careCARMENA trialNeoantigen loadSunitinib therapyAdvanced RCCAntigen spreadingImmune therapyUrologic evaluationFrontline settingCombination therapySurgical candidatesDNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms
Verschuur A, Hackeng W, Westerbeke F, Benhamida J, Basturk O, Selenica P, Raicu G, Molenaar I, van Santvoort H, Daamen L, Klimstra D, Yachida S, Luchini C, Singhi A, Geisenberger C, Brosens L. DNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms. Clinical Gastroenterology And Hepatology 2024, 22: 1245-1254.e10. PMID: 38382726, DOI: 10.1016/j.cgh.2024.02.007.Peer-Reviewed Original ResearchConceptsPancreatic neoplasmsMachine learning modelsAnalysis of biopsy specimensNonpancreatic neoplasmsNon-pancreatic originDiagnosis of pancreatic neoplasmsPrimary pancreatic neoplasmDiagnostic work-upArea under the curvePre-operative settingLearning modelsMethylation profilesPrimary tumorBiopsy specimensHistopathological diagnosisResected samplesDetecting neoplasmsDNA methylation signaturesTumor typesCancer entitiesLogistic regression modelsNeoplasmsClassifier performanceNeural networkConcordant classificationOncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.
Zhao J, Huang K, Chia D, Law J, Tan A, So J, Tan P, Sundar R. Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis. Journal Of Clinical Oncology 2024, 42: 392-392. DOI: 10.1200/jco.2024.42.3_suppl.392.Peer-Reviewed Original ResearchPeritoneal metastasisPrimary tumorWhole-exome sequencingARID1A mutationsGastric cancerMedian follow-up durationGS tumorsPrimary tumors of patientsMetachronous peritoneal metastasesAssociated with PMFollow-up durationGastric cancer tumorsPoor survival outcomesPrimary GC tumorsMetachronous PMAdvanced tumorsCDH1 mutationsSurgical resectionOncogenic aberrationsSurvival outcomesClinical outcomesPoor prognosisFollowed-upProspective cohortRHOA mutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply